等待肝移植期间接受抗病毒治疗患者的临床结局
该多中心回顾性观察研究分析了西班牙18家医院238例等待肝移植的丙型肝炎病毒(HCV)感染患者接受无干扰素抗病毒治疗的结局。代偿期肝硬化合并肝细胞癌(HCC)患者持续病毒学应答率显著高于失代偿期肝硬化伴或不伴HCC患者(92% vs 83%,p=0.042)。122例无HCC的失代偿期肝硬化患者中29例(24%)因改善被移除 waiting list,移除后中位随访88周,多数保持稳定。
要点
- 代偿期肝硬化合并HCC患者SVR率92%,显著高于失代偿期肝硬化伴或不伴HCC患者的83%(p=0.042)。
- 122例无HCC的失代偿期肝硬化患者中29例(24%)因临床改善被移除 waiting list。
- 基线MELD评分>20的患者无一例被移除 waiting list。
核心结论
- 抗病毒治疗在等待肝移植患者中安全有效,约四分之一失代偿期肝硬化患者可因临床改善被移除 waiting list,且多数保持稳定。
- 移除 waiting list 是一种安全策略,可节省器官并惠及其他更紧急的患者。
研究设计与样本
- 观察性、多中心、回顾性分析,数据来自西班牙18家医院前瞻性收集的等待肝移植的HCV阳性患者,接受无干扰素方案治疗。
- 共纳入238例患者;肝移植指征为失代偿期肝硬化(伴或不伴HCC)171例(72%),HCC 67例(28%)。
主要发现
- 持续病毒学应答率在代偿期肝硬化合并HCC患者为92%,在失代偿期肝硬化伴或不伴HCC患者为83%,差异显著(p=0.042)。
- 122例无HCC的失代偿期肝硬化患者中,29例(24%)因改善被移除 waiting list。
- 基线MELD评分>20的患者无一例被移除 waiting list。
- 移除后中位随访88周,3例出现临床失代偿,3例出现新发HCC;HCC患者中仅2例需重新列入 waiting list,其余23例保持稳定且无肝移植指征。
关键数值与推荐
- 持续病毒学应答率:代偿期肝硬化合并HCC患者92% vs 失代偿期肝硬化伴或不伴HCC患者83%(p=0.042)。
- 无HCC的失代偿期肝硬化患者移除 waiting list 比例:29/122(24%)。
- 基线MELD评分>20的患者无移除 waiting list 者。
- 移除后中位随访88周:临床失代偿3例,新发HCC 3例,重新列入 waiting list 2例,保持稳定23例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Antiviral therapy for the treatment of hepatitis C (HCV) infection has proved to be safe and efficacious in patients with cirrhosis awaiting liver transplantation (LT). However, the information regarding the clinical impact of viral eradication in patients on the waiting list is still limited. The aim of the study was to investigate the probability of delisting in patients who underwent antiviral therapy, and the clinical outcomes of these delisted patients. METHODS: Observational, multicenter and retrospective analysis was carried out on prospectively collected data from patients positive for HCV, treated with an interferon-free regimen, while awaiting LT in 18 hospitals in Spain. RESULTS: In total, 238 patients were enrolled in the study. The indication for LT was decompensated cirrhosis (with or without hepatocellular carcinoma [HCC]) in 171 (72%) patients, and HCC in 67 (28%) patients. Sustained virologic response (SVR) rate was significantly higher in patients with compensated cirrhosis and HCC (92% vs. 83% in patients with decompensated cirrhosis with or without HCC, p=0.042). Among 122 patients with decompensated cirrhosis without HCC, 29 (24%) were delisted due to improvement. No patient with baseline MELD score >20 was delisted. After delisting (median follow-up of 88weeks), three patients had clinical decompensations and three had de novo HCC. Only two of the patients with HCC had to be re-admitted onto the waiting list. The remaining 23 patients remained stable, with no indication for LT. CONCLUSIONS: Antiviral therapy is safe and efficacious in patients awaiting LT. A quarter of patients with decompensated cirrhosis can be delisted asa result of clinical improvement, which appears to be remain stable in most patients. Thus, delisting is a safe strategy that could spare organs and benefit other patients with a more urgent need. LAY SUMMARY: Antiviral therapy in patients awaiting liver transplantation is safe and efficacious. Viral eradication allows removal from the waiting list of a quarter of treated patients. Delisting because of clinical improvement is a safe strategy that can spare organs for patients in urgent need.
引用
- Pascasio JM, Vinaixa C, Ferrer MT, et al. Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation. J Hepatol. 2017. PMID: 28842296. doi:10.1016/j.jhep.2017.08.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。